---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-171647"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2025-08-01T23:59:59+00:00"
generated_at: "2026-05-17T21:46:51.998392+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Executive Chairman Harlan Waksal departs Lyra; CEO Palasis becomes Chair

## Summary
- Harlan W. Waksal's employment terminated effective August 1, 2025; he resigned from Board.
- Dr. Waksal eligible for severance per employment agreement upon signing separation and release.
- Maria Palasis, President & CEO, appointed Chair of the Board effective immediately.
- Jim Tobin remains as Lead Independent Director.

## SEC filing metadata
- accession: 0001193125-25-171647
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2025-08-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000119312525171647/0001193125-25-171647-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000119312525171647/d949358d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-171647
- JSON: https://secwatch.observer/filing/0001193125-25-171647.json
- Plain text: https://secwatch.observer/filing/0001193125-25-171647.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.